



From: [REDACTED] (SANTE) on behalf of [REDACTED] (SANTE)
Sent: 28 July 2020 10:31
To: [REDACTED]
Cc: [REDACTED] (SANTE); [REDACTED] (SANTE); [REDACTED]
RYS Andrzej Jan (SANTE); SANTE CONSULT-B; [REDACTED]
(SANTE)
Subject: RE: Roche Response to EU Pharma Strategy - Request for exchange

Dear [REDACTED]

On behalf of Mr Rys, we would like to thank you for your kind words and active participation in the workshop which indeed gave the opportunity to go beyond just insight on the stakeholders views but also allowed interaction of that insight among participants.

We welcome your input on the roadmap feedback mechanism and also invite you to fill in the online [survey](#) which is open till 15 September.

As regards a prospective meeting in the fall we would kindly ask that this is channelled through one of your representative organisations, as it would be very difficult from a resources point of view to meet individual companies separately during that busy period. Thank you for your understanding on this.

Wishing you a relaxing summer break.
Kind regards,



European Commission
Health and Food Safety Directorate General (SANTE)
Unit B5 Medicines-policy, authorisation and monitoring
[REDACTED]
B-1049 Brussels, Belgium

From: [REDACTED]
Sent: Thursday, July 23, 2020 5:58 PM
To: RYS Andrzej Jan (SANTE) <Andrzej.RYS@ec.europa.eu>
Cc: [REDACTED]
Subject: Roche Response to EU Pharma Strategy - Request for exchange

Dear Andrzej,

We would like to congratulate you and your team on a very well moderated and lively workshop on the EU Pharma Strategy last week. We particularly appreciate the insights it gave into the different views of various stakeholders.

The EU Pharma Strategy has drawn the full attention of Roche's senior leadership, as you can see from this [public interview with Padraic Ward](#), Head Pharma International at Roche. We are convinced that this is an unprecedented opportunity to realize our vision to "Re-establish Europe as a global medical innovation power-house by the end of the decade, delivering more health benefits to EU patients, while reducing overall costs to society and strengthening the economy". To that end, we consider it critical to expand the current pharma strategy into a long-term healthcare innovation strategy that will future-proof systems beyond crises, attract continued research investment and reward medical innovation.

Consistent with this vision, in [our response](#) to the consultation (Annex, attached), we identified a list of problems and opportunities for next steps. These are also consistent with a number of ambitions expressed by several stakeholders during the workshop, such as improving the regulatory framework to better connect the pharmaceutical and the medical device framework and advancing HTA and healthcare systems collaborations.

Following our submission, we are working with Roche experts across different functions to consolidate our thinking on specific opportunities and to collect examples and further data to support this.

As a continuation of the good conversation started with Mr. Martin Seychell, we would welcome an exchange, eventually later this fall, on collaborative ways to gradually advance the current EU framework and ecosystem that supports innovation in personalised healthcare at the crossroads of pharmaceuticals, medical devices, diagnostics and digital. Roche is looking forward to working together with you along this journey.

Wishing you a lovely summer and kind regards,



--



F. Hoffmann-La Roche Ltd
Drug Regulatory Affairs
PDR



Switzerland

Phone [REDACTED]

Mobile [REDACTED]

E-Mail [REDACTED]

Confidentiality Note: This message is intended only for the use of the named recipient(s) and may contain confidential and/or privileged information. If you are not the intended recipient, please contact the sender and delete this message. Any unauthorized use of the information contained in this message is prohibited.